JP2012528810A - サーファクタントタンパク質b(sp−b)およびサーファクタントタンパク質c(sp−c)の類似体を含有する改善された再構築サーファクタント組成物 - Google Patents
サーファクタントタンパク質b(sp−b)およびサーファクタントタンパク質c(sp−c)の類似体を含有する改善された再構築サーファクタント組成物 Download PDFInfo
- Publication number
- JP2012528810A JP2012528810A JP2012513503A JP2012513503A JP2012528810A JP 2012528810 A JP2012528810 A JP 2012528810A JP 2012513503 A JP2012513503 A JP 2012513503A JP 2012513503 A JP2012513503 A JP 2012513503A JP 2012528810 A JP2012528810 A JP 2012528810A
- Authority
- JP
- Japan
- Prior art keywords
- surfactant
- weight
- reconstructed
- protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004094 surface-active agent Substances 0.000 title claims abstract description 139
- 239000000203 mixture Substances 0.000 title claims description 56
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 title description 11
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 title 2
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 title 2
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 43
- 229920001184 polypeptide Polymers 0.000 claims abstract description 39
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 claims abstract description 21
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims abstract description 15
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 24
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 22
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 19
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- NRBLBEWYHRQCIG-AKVLDSKYSA-N [(2R)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-octadec-9-enoxy]propyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OCCCCCCCC\C=C/CCCCCCCC NRBLBEWYHRQCIG-AKVLDSKYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 claims description 4
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 230000002028 premature Effects 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 238000011268 retreatment Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 abstract description 13
- 239000003580 lung surfactant Substances 0.000 abstract description 7
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 229940066294 lung surfactant Drugs 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 description 22
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 16
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000007789 gas Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229940092456 curosurf Drugs 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000015227 regulation of liquid surface tension Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PAZGBAOHGQRCBP-ZCXUNETKSA-N 1-Palmitoyl-2-oleoylglycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-ZCXUNETKSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010037370 Pulmonary contusion Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Cosmetics (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
Description
本発明は、呼吸促迫症候群(呼吸促迫症候群:RDS:respiratory distress syndrome)および他の呼吸器障害の予防および/または治療に適した再構築肺サーファクタントに関する。
ヒト肺は、肺胞と呼ばれる多数の小さな空気嚢からなり、ここで肺の血液と気泡空隙との間でガスが交換される。健康な個体では、この交換は、息の吐き出し、すなわち呼気の終末に肺が虚脱するのを防ぐタンパク質含有サーファクタント複合体の存在により媒介される。
本発明は、
a)式:IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL(配列番号:1)により表される配列からなる天然サーファクタントタンパク質SP−Cのポリペプチド類似体1.2重量%から1.8重量%と、
b)式:CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS(配列番号:2)により表される配列からなる天然サーファクタントタンパク質SP−Bのポリペプチド類似体0.1重量%から0.5重量%と、
45:55から55:45の範囲の重量比でのモノ不飽和リン脂質と飽和リン脂質とを含み、前記量の全てが再構築サーファクタントの総重量に対して計算される、
再構築サーファクタントに関する。
サーファクタント製剤のための「サーファクタント活性」は、表面張力を低下させる能力として定義される。
i)肺コンプライアンスの指標である満杯量、すなわち1回換気量(1回呼吸量)および
ii)呼気の終了時における肺胞気拡張(alveolar air expansion)または開存(alveolar air patency)の指標、すなわち、呼気の終末に肺胞において安定なリン脂質膜を形成する能力の指標である肺ガス量、
を測定することによりテストされる。
図1は、本発明の再構築サーファクタント(N3)対Curosurf(登録商標)および未処置動物(n=動物の数)の時間/圧力の関数としての、1回換気量(ml/kg)に関する結果を示す図である。
WO 2008/044109で一般的に開示されたサーファクタント組成物におけるリン脂質、ならびにSP−B類似体およびSP−C類似体の相対量によって、粘度がいかに影響されるか、ならびに前記成分が、再構築サーファクタントにおいて互いにいかに影響されるかを調べるため、多因子実験デザインが構築された。
a)式:IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL(配列番号:1)により表される配列からなる天然サーファクタントタンパク質SP−Cのポリペプチド類似体1.2重量%から1.8重量%と、
b)式:CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS(配列番号:2)により表される配列からなる天然サーファクタントタンパク質SP−Bのポリペプチド類似体0.1重量%から0.5重量%と、
45:55から55:45の範囲の重量比でのモノ不飽和リン脂質と飽和リン脂質と、を含み、前記量の全てが再構築サーファクタントの総重量に対して計算される、再構築サーファクタントに関する。
a)式:IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL(配列番号:1)により表される配列からなる天然サーファクタントタンパク質SP−Cのポリペプチド類似体の約1.5重量%と、
b)式:CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS(配列番号:2)により表される配列からなる天然サーファクタントタンパク質SP−Bのポリペプチド類似体の約0.2重量%と、
c)約50:50の重量比での1,2−ジパルミトイル−sn−グリセロ−3−ホスホコリン(DPPC)および1−パルミトイル−2−オレイル−sn−グリセロ−3−ホスホグリセロール(POPG)と
を含み、前記量の全てが再構築サーファクタントの総重量に対して計算される、再構築サーファクタントに関する。
a)式:IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL(配列番号:1)により表される配列からなる天然サーファクタントタンパク質SP−Cのポリペプチド類似体の約1.5重量%と、
b)式:CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS(配列番号:2)により表される配列からなる天然サーファクタントタンパク質SP−Bのポリペプチド類似体の約0.2重量%と、
c)1,2−ジパルミトイル−sn−グリセロ−3−ホスホコリン(DPPC)の約49.15重量%と、
d)1−パルミトイル−2−オレイル−sn−グリセロ−3−ホスホグリセロール(POPG)の約49.15重量%と
を含み、前記量の全てが再構築サーファクタントの総重量に基づいて計算される、再構築サーファクタントに関する。
a)式:IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL(配列番号:1)により表される配列からなる天然サーファクタントタンパク質SP−Cのポリペプチド類似体の約1.5重量%、
b)式:CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS(配列番号:2)により表される配列からなる天然サーファクタントタンパク質SP−Bのポリペプチド類似体の約0.2重量%、
c)1,2−ジパルミトイル−sn−グリセロ−3−ホスホコリン(DPPC)の約49.15重量%、および
d)1−パルミトイル−2−オレイル−sn−グリセロ−3−ホスホグリセロール(POPG)の約49.15重量%
(前記量の全てが再構築サーファクタントの総重量に基づいて計算される)から構成される再構築サーファクタント約80mg/mlを含む、生理食塩水中の水性懸濁液の形態での医薬製剤に関する。
例
例1 粘度に対する成分の影響
製剤に対する成分の影響を粘度に関して評価するために、多因子実験デザインが構築される。異なるパーセンテージのポリペプチドSP−C33(Leu)およびox−Mini−B(Leu)、ならびに異なる比のDPPCおよびPOPG Naをテストする。
1:1比でのDPPC:POPG Na、例1の表1に組成物N3に関して報告されたパーセンテージ量でのSPC−33(Leu)およびox Mini−B(Leu)の混合物を、クロロホルム/エタノール98:2(v/v)に溶解する。
例2の再構築サーファクタントは、妊娠在胎期間27日での子宮摘出により得られた早産新生児ウサギにおいてアッセイする。実験は、呼気終末陽圧(PEEP:positive end expiratory pressure)を適用せずに行う。
Claims (15)
- a)式:IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL(配列番号:1)により表される配列からなる天然サーファクタントタンパク質SP−Cのポリペプチド類似体の1.2重量%から1.8重量%と、
b)式:CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS(配列番号:2)により表される配列からなる天然サーファクタントタンパク質SP−Bのポリペプチド類似体の0.1重量%から0.5重量%と、
45:55から55:45の範囲の重量比でのモノ不飽和リン脂質と飽和リン脂質と、
を含み、
前記量の全てが再構築サーファクタントの総重量に対して計算される、再構築サーファクタント組成物。 - a)式:IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL(配列番号:1)により表される配列からなる天然サーファクタントタンパク質SP−Cのポリペプチド類似体の約1.5重量%と、
b)式:CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS(配列番号:2)により表される配列からなる天然サーファクタントタンパク質SP−Bのポリペプチド類似体の約0.2重量%と、
c)約50:50の重量比での1,2−ジパルミトイル−sn−グリセロ−3−ホスホコリン(DPPC)および1−パルミトイル−2−オレイル−sn−グリセロ−3−ホスホグリセロール(POPG)と
を含み、前記量の全てが再構築サーファクタントの総重量に対して計算される、請求項1に記載の再構築サーファクタント。 - a)式:IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL(配列番号:1)により表される配列からなる天然サーファクタントタンパク質SP−Cのポリペプチド類似体の約1.5重量%と、
b)式:CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS(配列番号:2)により表される配列からなる天然サーファクタントタンパク質SP−Bのポリペプチド類似体の約0.2重量%と、
c)1,2−ジパルミトイル−sn−グリセロ−3−ホスホコリン(DPPC)の約49.15重量%と、
d)1−パルミトイル−2−オレイル−sn−グリセロ−3−ホスホグリセロール(POPG)の約49.15重量%と
を含み、前記量の全てが再構築サーファクタントの総重量に基づいて計算される、請求項2に記載の再構築サーファクタント。 - 配列番号:2のポリペプチドが、1位および33位における2つのシステイン残基間、ならびに/または、4位および27位における2つのシステイン残基間の分子内ジスルフィド結合を有するジスルフィド結合分子の形態である、請求項1から3のいずれか一項に記載の再構築サーファクタント。
- POPGが薬学的に許容される塩の形態である、請求項1から4のいずれか一項に記載の再構築サーファクタント。
- 塩がナトリウム塩である、請求項5に記載の再構築サーファクタント。
- 前記ポリペプチドの各々が薬学的に許容される塩の形態で存在する、請求項1から6のいずれか一項に記載の再構築サーファクタント。
- 塩が酢酸塩である、請求項7に記載の再構築サーファクタント。
- 請求項1から8のいずれか一項に記載の再構築サーファクタントを含む医薬製剤であって、溶液、分散液、懸濁液または乾燥粉末の形態であり、場合により1つまたは複数の薬学的に許容される担体との組合せである医薬製剤。
- 前記製剤が水性懸濁液の形態である、請求項9に記載の医薬組成物。
- 再構築サーファクタントが、水性懸濁液の0.1mg/mlから160mg/mlの間の濃度を有する、請求項10に記載の医薬製剤。
- a)第1の単位投与形態における粉末形態での請求項1から8のいずれか一項に記載の再構築サーファクタントと、
b)第2の単位投与形態における薬学的に許容される担体と、
c)前記第1および第2の投与形態を含有するための容器手段と
を含むキット。 - 医薬品として使用するための、請求項1から8のいずれか一項に記載の再構築サーファクタント。
- 未熟児における呼吸促迫症候群(RDS)の治療もしくは予防、またはサーファクタント欠損もしくは機能不全に関連した他の疾患の治療もしくは予防に使用するための、請求項1から8のいずれか一項に記載の再構築サーファクタント。
- 疾患が、成人におけるRDS(ARDS)、胎便吸引症候群(MAS)、および気管支肺異形成症(BPD)を含む、請求項14に記載のサーファクタント。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09162052 | 2009-06-05 | ||
EP09162052.6 | 2009-06-05 | ||
PCT/EP2010/003293 WO2010139442A1 (en) | 2009-06-05 | 2010-05-31 | Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012528810A true JP2012528810A (ja) | 2012-11-15 |
JP5666569B2 JP5666569B2 (ja) | 2015-02-12 |
Family
ID=41055357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012513503A Active JP5666569B2 (ja) | 2009-06-05 | 2010-05-31 | サーファクタントタンパク質b(sp−b)およびサーファクタントタンパク質c(sp−c)の類似体を含有する改善された再構築サーファクタント組成物 |
Country Status (36)
Country | Link |
---|---|
US (1) | US8399406B2 (ja) |
EP (1) | EP2438086B1 (ja) |
JP (1) | JP5666569B2 (ja) |
KR (1) | KR101668137B1 (ja) |
CN (1) | CN102459327B (ja) |
AR (1) | AR076973A1 (ja) |
AU (1) | AU2010256066B2 (ja) |
BR (1) | BRPI1010120B1 (ja) |
CA (1) | CA2764454C (ja) |
CL (1) | CL2011003003A1 (ja) |
CO (1) | CO6470858A2 (ja) |
CY (1) | CY1118676T1 (ja) |
DK (1) | DK2438086T3 (ja) |
EA (1) | EA021163B1 (ja) |
ES (1) | ES2621974T3 (ja) |
GE (1) | GEP20135967B (ja) |
HK (1) | HK1166332A1 (ja) |
HR (1) | HRP20170445T1 (ja) |
HU (1) | HUE034053T2 (ja) |
IL (1) | IL216718A (ja) |
JO (1) | JO3226B1 (ja) |
LT (1) | LT2438086T (ja) |
MA (1) | MA33374B1 (ja) |
ME (1) | ME01279B (ja) |
MX (1) | MX2011012951A (ja) |
MY (1) | MY159464A (ja) |
NZ (1) | NZ596848A (ja) |
PE (1) | PE20120541A1 (ja) |
PL (1) | PL2438086T3 (ja) |
PT (1) | PT2438086T (ja) |
SG (1) | SG176305A1 (ja) |
SI (1) | SI2438086T1 (ja) |
TN (1) | TN2011000558A1 (ja) |
TW (1) | TWI457132B (ja) |
UA (1) | UA103526C2 (ja) |
WO (1) | WO2010139442A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8968786B2 (en) | 2007-06-22 | 2015-03-03 | Board Of Regents, The University Of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
CA2829629A1 (en) * | 2011-03-10 | 2012-09-13 | Board Of Regents, The University Of Texas System | Protein nanoparticle dispersions |
EP2812018B1 (en) * | 2012-02-09 | 2018-12-05 | University Of Rochester | Novel sp-b&sp-c peptides, synthetic lung surfactants, and use thereof |
ES2644317T3 (es) | 2012-11-21 | 2017-11-28 | Chiesi Farmaceutici S.P.A. | Tensioactivos pulmonares reconstituidos |
CN104382942A (zh) * | 2014-11-05 | 2015-03-04 | 烟台东诚药业集团股份有限公司 | 一种猪肺表面活性物质混悬液制备新工艺 |
EP3106090A1 (en) | 2015-06-15 | 2016-12-21 | CHIESI FARMACEUTICI S.p.A. | System for effective breath-synchronized delivery of medicament to the lungs |
CN107666933A (zh) | 2015-04-22 | 2018-02-06 | 奇斯药制品公司 | 用于药物有效地呼吸同步递送到肺部的方法和系统 |
US11311691B2 (en) | 2015-04-28 | 2022-04-26 | Chiesi Farmaceutici S.P.A | Device for facilitating the administration of a medicament to the lung by a catheter |
EP3452041A4 (en) * | 2016-03-07 | 2020-11-11 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | COMPOSITIONS AND METHOD OF ADMINISTRATION OF PPAR AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS |
CA3028551A1 (en) | 2016-07-28 | 2018-02-01 | Chiesi Farmaceutici S.P.A. | Method and system for delivery of an aerosolized medicament |
KR102395835B1 (ko) | 2016-08-24 | 2022-05-10 | 키에시 파르마슈티시 엣스. 피. 에이. | 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제 |
BR112019008169A2 (pt) | 2016-10-26 | 2019-07-09 | Chiesi Farm Spa | dispositivo para facilitar o posicionamento de um cateter, sistema para entrega de um medicamento em aerossol por meio de um cateter, método para utilização de um dispositivo e kit |
EP3558376B1 (en) | 2016-12-22 | 2021-10-20 | Chiesi Farmaceutici S.p.A. | A therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving bpd |
TW201927286A (zh) | 2017-12-15 | 2019-07-16 | 義大利商凱西製藥公司 | 用於噴霧投藥之包含肺表面張力素的藥學調配物 |
WO2019115771A1 (en) | 2017-12-15 | 2019-06-20 | Pari Pharma Gmbh | Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method |
AU2019260526A1 (en) | 2018-04-23 | 2020-11-19 | Chiesi Farmaceutici S.P.A. | A therapeutic combination comprising a pulmonary surfactant and a steroid for the prophylaxis of BPD |
EP3666316A1 (en) | 2018-12-14 | 2020-06-17 | PARI Pharma GmbH | Aerosol delivery device and method of operating the aerosol delivery device |
EP3666315A1 (en) | 2018-12-14 | 2020-06-17 | PARI Pharma GmbH | Aerosol delivery device and method of operating the aerosol delivery device |
EP3843105A1 (en) | 2019-12-23 | 2021-06-30 | PARI Pharma GmbH | Control device for aerosol nebulizer system |
US20230257446A1 (en) | 2020-01-28 | 2023-08-17 | Chiesi Farmaceutici S.P.A. | Polypeptides having improved properties |
EP4366691A1 (en) | 2021-07-05 | 2024-05-15 | Chiesi Farmaceutici S.p.A. | Process for the preparation of a pulmonary surfactant |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007500199A (ja) * | 2003-05-30 | 2007-01-11 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 合成界面活性剤のための新規な脂質混合物 |
WO2008044109A1 (en) * | 2006-10-13 | 2008-04-17 | Chiesi Farmaceutici S.P.A. | Reconstituted surfactants having improved properties |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2372558A1 (en) | 1999-06-11 | 2000-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
KR101243867B1 (ko) * | 2005-05-11 | 2013-03-20 | 야마사 쇼유 가부시키가이샤 | 폐서팩턴트 단백질의 안정화법 |
WO2008011559A2 (en) | 2006-07-20 | 2008-01-24 | University Of Rochester | Synthetic lung surfactant and use thereof |
EP1997502A1 (en) * | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
-
2010
- 2010-05-27 US US12/788,480 patent/US8399406B2/en active Active
- 2010-05-31 KR KR1020117028394A patent/KR101668137B1/ko active IP Right Grant
- 2010-05-31 CA CA2764454A patent/CA2764454C/en active Active
- 2010-05-31 CN CN201080024545.6A patent/CN102459327B/zh active Active
- 2010-05-31 DK DK10724708.2T patent/DK2438086T3/en active
- 2010-05-31 BR BRPI1010120-9A patent/BRPI1010120B1/pt active IP Right Grant
- 2010-05-31 LT LTEP10724708.2T patent/LT2438086T/lt unknown
- 2010-05-31 PT PT107247082T patent/PT2438086T/pt unknown
- 2010-05-31 MA MA34471A patent/MA33374B1/fr unknown
- 2010-05-31 GE GEAP201012486A patent/GEP20135967B/en unknown
- 2010-05-31 PL PL10724708T patent/PL2438086T3/pl unknown
- 2010-05-31 ME MEP-2011-197A patent/ME01279B/me unknown
- 2010-05-31 EA EA201190292A patent/EA021163B1/ru unknown
- 2010-05-31 SI SI201031433A patent/SI2438086T1/sl unknown
- 2010-05-31 UA UAA201114285A patent/UA103526C2/ru unknown
- 2010-05-31 AU AU2010256066A patent/AU2010256066B2/en active Active
- 2010-05-31 HU HUE10724708A patent/HUE034053T2/en unknown
- 2010-05-31 JP JP2012513503A patent/JP5666569B2/ja active Active
- 2010-05-31 EP EP10724708.2A patent/EP2438086B1/en active Active
- 2010-05-31 MX MX2011012951A patent/MX2011012951A/es active IP Right Grant
- 2010-05-31 SG SG2011089299A patent/SG176305A1/en unknown
- 2010-05-31 MY MYPI2011005866A patent/MY159464A/en unknown
- 2010-05-31 WO PCT/EP2010/003293 patent/WO2010139442A1/en active Application Filing
- 2010-05-31 NZ NZ596848A patent/NZ596848A/xx unknown
- 2010-05-31 PE PE2011002046A patent/PE20120541A1/es active IP Right Grant
- 2010-05-31 ES ES10724708.2T patent/ES2621974T3/es active Active
- 2010-06-03 TW TW099117884A patent/TWI457132B/zh active
- 2010-06-03 JO JOP/2010/0185A patent/JO3226B1/ar active
- 2010-06-03 AR ARP100101970A patent/AR076973A1/es not_active Application Discontinuation
-
2011
- 2011-11-04 TN TNP2011000558A patent/TN2011000558A1/en unknown
- 2011-11-25 CL CL2011003003A patent/CL2011003003A1/es unknown
- 2011-12-01 IL IL216718A patent/IL216718A/en active IP Right Grant
- 2011-12-02 CO CO11166483A patent/CO6470858A2/es active IP Right Grant
-
2012
- 2012-07-18 HK HK12107033.0A patent/HK1166332A1/xx unknown
-
2017
- 2017-02-24 CY CY20171100262T patent/CY1118676T1/el unknown
- 2017-03-21 HR HRP20170445TT patent/HRP20170445T1/hr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007500199A (ja) * | 2003-05-30 | 2007-01-11 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 合成界面活性剤のための新規な脂質混合物 |
WO2008044109A1 (en) * | 2006-10-13 | 2008-04-17 | Chiesi Farmaceutici S.P.A. | Reconstituted surfactants having improved properties |
Non-Patent Citations (2)
Title |
---|
JPN6014016070; Walther, F.J. et al.: 'Surfactant protein B and C analogues' Mol.Genet.Metab. Vol.71, No.1-2, 2000, p.342-351 * |
JPN6014016071; Palmblad, M. et al.: 'Biophysical activity of an artificial surfactant containing an analogue of surfactant protein (SP)-C' Biochem.J. Vol.339, No.2, 1999, p.381-386 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5666569B2 (ja) | サーファクタントタンパク質b(sp−b)およびサーファクタントタンパク質c(sp−c)の類似体を含有する改善された再構築サーファクタント組成物 | |
JP5575639B2 (ja) | 改善された特性を有する再構成サーファクタント | |
RU2656185C2 (ru) | Реконструированные сурфактанты легких | |
RU2748417C2 (ru) | Стабильная фармацевтическая композиция, включающая восстановленную композицию легочного сурфактанта | |
KR20160103211A (ko) | 계면활성 단백질 b(sp-b) 및 계면활성 단백질 c(sp-c)의 유사체를 포함하는 합성 폐 계면활성제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130326 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140414 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140701 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5666569 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |